Company Update: Merck & Co Inc (NYSE:MRK) – Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
March 31, 2015 at 08:00 AM EDT
[Business Wire] – Syndax Pharmaceuticals, Inc., and Merck , known as MSD outside the United States and Canada, announced today that they have entered into a clinical trial collaboration to evaluate the safety . . . → Read More: Company Update: Merck & Co Inc (NYSE:MRK) – Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma Similar Articles: Market Update (NYSE:MRK): Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia Stock Update: Merck & Co Inc (NYSE:MRK) – Merck, Bristol heat up immunotherapy race in lung cancer Market Update: Merck & Co Inc (NYSE:MRK) – New Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time